Pramlintide

World Peptide Foundation

Where is Pramlintide being studied?

Find registered human studies, phases, products, recruitment status and reported research locations around the world. Registry search matches are separate from this profile’s reviewed evidence.

Find studies for Pramlintide →Worldwide registry directory

Scientific intelligence record

Experience 2.0

Amylin analog

Pramlintide is an amylin analog investigated in metabolic care. Evidence about this specific compound must be separated from evidence about newer long-acting amylin analogs and combinations.

Record status

Traceability partial

Last meaningful update: 9/26/2026

Evidence searched through:: Not recorded
Assessment updated:: 9/26/2026
Documented human review:: No documented human review recorded
Automated scientific assessment:: None recorded
AI source check:: 9/26/2026

Published source links and profile text pass separate gates. Only a documented human review is labelled as human review; an automated scientific assessment applies deterministic checks, and an AI source check confirms only that a source exists and matches its identifiers. A source count alone does not establish a review.

Evidence coverage has three distinct layers. The corpus count is a transparent screening inventory, the featured set contains study-level tiering and interpretation, and the published-source count contains records promoted through the institutional publication workflow. Source validation, editorial publication, and scientific appraisal are separate decisions; these numbers must not be merged.

Ranked research corpus

500

Categorized publications with provisional ranking; scientific review remains separate.

Featured tiered studies

Cornerstone publications with study-level interpretation, limitations, and tier disclosure.

Research domains

Clinical and scientific questions synthesized independently across the evidence atlas.

Published source records

184

Database records promoted through the governed publication workflow—not the corpus total.

Corpus generated 2026-09-18. Counts remain separately labeled so screening is not represented as completed review.

Human experience · separate evidence stream

No community pattern is displayed yet

Eligible observations remain below the privacy and reliability threshold. WPF will not convert a handful of reports into a percentage, trend, or clinical claim.

Observation is valuable human context. It is not evidence of causation, efficacy, or safety.

Public display gate

n ≥ 20 eligible observations

Exact progress remains private before the threshold.

Contribute an observation Archive details

Intelligence snapshot

The state of the record

A compact view of what is represented, what remains unresolved, and how completely the record can be traced.

Ranked research corpus

500

Categorized screening records; proposed rankings remain pending human appraisal.

Featured tiered studies

Cornerstone studies with published study-level interpretation and tier disclosure.

Research domains

Independent evidence dossiers covering the major research questions.

Published source records

184

Source records published through the governed workflow; this count does not certify scientific conclusions.

Contradictions

Conflicting evidence relationships that remain visible.

Research gaps

Questions the current record identifies as unresolved.

Connected media

Media records explicitly linked to this scientific record.

What we know

Evidence, claims, and boundaries

The project separates represented evidence from qualification, contradiction, uncertainty, and what the evidence does not establish.

Reconciled domain conclusions

6 published domain syntheses connected to 0 featured studies

Pramlintide no longer relies on the legacy “no public claim” state. Each research domain publishes a bounded synthesis, confidence level, evidence context, limitations, geographic applicability, regulatory interpretation, and research gaps. Publication of these syntheses is separate from the scientific review status shown above.

Inspect the reconciled evidence atlas

Inspect the published evidence record184 governed records · titles, provenance, and original-source linksOpen records ↓

2004Phase 1–2 human evidence

Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial.

Content-verified record concerning Pramlintide: "Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial." Abstract excerpt: The autoimmune-mediated destruction of pancreatic beta-cells in Type 1 diabetes mellitus renders patients deficient in two glucoregulatory peptide hormones, insulin and amylin. With insulin replacement alone, most patients do not achieve glycaemic goals. We aimed to determine the long-term efficacy and safety of adjunctive therapy with pramlintide, a synthetic human amylin analogue, in patients wi

Source: peer_reviewed_research
DOI: 10.1111/j.1464-5491.2004.01319.x
PubMed: 15498087

Open original source

2007Phase 1–2 human evidence

Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study.

Content-verified record concerning Pramlintide: "Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study." Abstract excerpt: In previous 1-yr trials, treatment with pramlintide (120 microg), an analog of the beta-cell hormone amylin, induced sustained reductions in A1C and body weight in insulin-using subjects with type 2 diabetes. To assess the potential of pramlintide as an antiobesity agent, we assessed the weight effect, safety, and tolerability of pramlintide in non-insulin-treated obese subjects with and without t

Source: peer_reviewed_research
DOI: 10.1210/jc.2006-2003
PubMed: 17504894

Open original source

2003Phase 1–2 human evidence

Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial.

Content-verified record concerning Pramlintide: "Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial." Abstract excerpt: Mealtime amylin replacement with the human amylin analog pramlintide, as an adjunct to mealtime insulin replacement, reduces postprandial glucose excursions in patients with type 2 diabetes. The aim of the present study was to assess the long-term efficacy and safety of pramlintide in this patient population. In a 52-week, double-blind, placebo-controlled, parallel-group, multicenter study, 656 pa

Source: peer_reviewed_research
DOI: 10.2337/diacare.26.3.784
PubMed: 12610038

Open original source

2010Phase 1–2 human evidence

Patient reported outcomes in adults with type 2 diabetes on basal insulin randomized to addition of mealtime pramlintide or rapid-acting insulin analogs.

Content-verified record concerning Pramlintide: "Patient reported outcomes in adults with type 2 diabetes on basal insulin randomized to addition of mealtime pramlintide or rapid-acting insulin analogs." Abstract excerpt: To determine whether treatment satisfaction and quality of life were affected by adding mealtime pramlintide or rapid-acting insulin analogs (RAIAs) to basal insulin therapy for patients with inadequately controlled type 2 diabetes. In this 24-week open-label, multicenter study of adults with type 2 diabetes, mealtime pramlintide (PRAM) (120 microg fixed dose; n = 56) or titrated RAIAs (n = 56) wa

Source: peer_reviewed_research
DOI: 10.1185/03007991003634759
PubMed: 20199136

Open original source

2009Phase 1–2 human evidence

Randomized comparison of pramlintide or mealtime insulin added to basal insulin treatment for patients with type 2 diabetes.

Content-verified record concerning Pramlintide: "Randomized comparison of pramlintide or mealtime insulin added to basal insulin treatment for patients with type 2 diabetes." Abstract excerpt: To compare the efficacy and safety of adding mealtime pramlintide or rapid-acting insulin analogs (RAIAs) to basal insulin for patients with inadequately controlled type 2 diabetes. In a 24-week open-label, multicenter study, 113 patients were randomly assigned 1:1 to addition of mealtime pramlintide (120 microg) or a titrated RAIA to basal insulin and prior oral antihyperglycemic drugs (OADs). At

Source: peer_reviewed_research
DOI: 10.2337/dc09-0395
PubMed: 19502544

Open original source

2020Phase 1–2 human evidence

A Novel Dual-Hormone Insulin-and-Pramlintide Artificial Pancreas for Type 1 Diabetes: A Randomized Controlled Crossover Trial.

Content-verified record concerning Pramlintide: "A Novel Dual-Hormone Insulin-and-Pramlintide Artificial Pancreas for Type 1 Diabetes: A Randomized Controlled Crossover Trial." Abstract excerpt: The rapid insulin-alone artificial pancreas improves glycemia in type 1 diabetes but daytime control remains suboptimal. We propose two novel dual-hormone artificial pancreas systems. We conducted a randomized crossover trial comparing a rapid insulin-alone artificial pancreas with rapid insulin-and-pramlintide and with regular insulin-and-pramlintide artificial pancreas systems in adults with typ

Source: peer_reviewed_research
DOI: 10.2337/dc19-1922
PubMed: 31974099

Open original source

2002Phase 1–2 human evidence

A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes.

Content-verified record concerning Pramlintide: "A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes." Abstract excerpt: To assess the effect of mealtime amylin replacement with pramlintide on long-term glycemic and weight control in patients with type 1 diabetes. In a 52-week, double-blind, placebo-controlled, multicenter study, 480 patients with type 1 diabetes were randomized to receive preprandial injections of placebo or 30 microg pramlintide q.i.d., in addition to existing insulin regimens. At week 20, pramlin

Source: peer_reviewed_research
DOI: 10.2337/diacare.25.4.724
PubMed: 11919132

Open original source

2009Phase 1–2 human evidence

Pramlintide lowered glucose excursions and was well-tolerated in adolescents with type 1 diabetes: results from a randomized, single-blind, placebo-controlled, crossover study.

Content-verified record concerning Pramlintide: "Pramlintide lowered glucose excursions and was well-tolerated in adolescents with type 1 diabetes: results from a randomized, single-blind, placebo-controlled, crossover study." Abstract excerpt: To evaluate the pharmacokinetics, pharmacodynamics, safety, and tolerability of pramlintide in treating adolescents with type 1 diabetes. Twelve subjects (9 females, 3 males, age 12 to 17 years; A1C, 8.4%; body mass index, 25 kg/m(2)) were randomized to pramlintide (15 or 30 microg) or placebo administered before a standardized breakfast. Insulin lispro (50% of usual mealtime dose) was injected se

Source: peer_reviewed_research
DOI: 10.1016/j.jpeds.2009.03.012
PubMed: 19464026

Open original source

2024Phase 1–2 human evidence

Simple meal announcements and pramlintide delivery versus carbohydrate counting in type 1 diabetes with automated fast-acting insulin aspart delivery: a randomised crossover trial in Montreal, Canada.

Content-verified record concerning Pramlintide: "Simple meal announcements and pramlintide delivery versus carbohydrate counting in type 1 diabetes with automated fast-acting insulin aspart delivery: a randomised crossover trial in Montreal, Canada." Abstract excerpt: In type 1 diabetes, carbohydrate counting is the standard of care to determine prandial insulin needs, but it can negatively affect quality of life. We developed a novel insulin-and-pramlintide closed-loop system that replaces carbohydrate counting with simple meal announcements. We performed a randomised crossover trial assessing 14 days of (1) insulin-and-pramlintide closed-loop system with simp

Source: peer_reviewed_research
DOI: 10.1016/s2589-7500(24)00092-x
PubMed: 38906614

Open original source

2018Phase 1–2 human evidence

Control of Postprandial Hyperglycemia in Type 1 Diabetes by 24-Hour Fixed-Dose Coadministration of Pramlintide and Regular Human Insulin: A Randomized, Two-Way Crossover Study.

Content-verified record concerning Pramlintide: "Control of Postprandial Hyperglycemia in Type 1 Diabetes by 24-Hour Fixed-Dose Coadministration of Pramlintide and Regular Human Insulin: A Randomized, Two-Way Crossover Study." Abstract excerpt: Healthy pancreatic β-cells secrete the hormones insulin and amylin in a fixed ratio. Both hormones are lacking in type 1 diabetes, and postprandial glucose control using insulin therapy alone is difficult. This study tested the pharmacodynamic effects of the amylin analog pramlintide and insulin delivered in a fixed ratio over a 24-h period. Patients with type 1 diabetes were stabilized on i

Source: peer_reviewed_research
DOI: 10.2337/dc18-1091
PubMed: 30213882

Open original source

2006Phase 1–2 human evidence

A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes.

Content-verified record concerning Pramlintide: "A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes." Abstract excerpt: To assess safety, efficacy, and tolerability of pramlintide dose escalation with proactive mealtime insulin reduction, followed by insulin optimization, in patients with type 1 diabetes. This 29-week, double-blind, placebo-controlled study randomized 296 patients to pramlintide or placebo as an adjunct to insulin. During initiation, pramlintide was escalated from 15 to 60 microg/meal (15-microg in

Source: peer_reviewed_research
DOI: 10.2337/dc06-0042
PubMed: 17003291

Open original source

2024Observational human evidence

A model of subcutaneous pramlintide pharmacokinetics and its effect on gastric emptying: Proof-of-concept based on populational data.

Content-verified record concerning Pramlintide: "A model of subcutaneous pramlintide pharmacokinetics and its effect on gastric emptying: Proof-of-concept based on populational data." Abstract excerpt: Pramlintide, an amylin analog, has been coming up as an agent in type 1 diabetes dual-hormone therapies (insulin/pramlintide). Since pramlintide slows down gastric emptying, it allows for easing glucose control and reducing the burden of meal announcements. Pre-clinical in silico evaluations are a key step in the development of any closed-loop strategy. However, mathematical models are needed, and

Source: peer_reviewed_research
DOI: 10.1016/j.cmpb.2023.107968
PubMed: 38064957

Open original source

2010Observational human evidence

Safety of pramlintide added to mealtime insulin in patients with type 1 or type 2 diabetes: a large observational study.

Content-verified record concerning Pramlintide: "Safety of pramlintide added to mealtime insulin in patients with type 1 or type 2 diabetes: a large observational study." Abstract excerpt: The objective of this Phase 4, open-label, multicentre, observational study was to fulfil food and drug administration (FDA) postapproval requirement to evaluate in healthcare practices the risk of insulin-induced severe hypoglycaemia following initiation of pramlintide therapy in N = 1297 patients with type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) with inadequate glycaemic c

Source: peer_reviewed_research
DOI: 10.1111/j.1463-1326.2010.01201.x
PubMed: 20518811

Open original source

2000Animal research

Kinetics of pramlintide degradation in aqueous solution as a function of temperature and pH.

Content-verified record concerning Pramlintide: "Kinetics of pramlintide degradation in aqueous solution as a function of temperature and pH." Abstract excerpt: The stability of the 37-amino acid peptide pramlintide, in aqueous solution, was studied as a function of pH and temperature. Samples of pramlintide formulated as a parenteral product were exposed to elevated temperatures and to realistic storage conditions for as long as 30 months. Pramlintide degradation was monitored by three high-performance liquid chromatography (HPLC) methods: a reversed-pha

Source: peer_reviewed_research
DOI: 10.1208/pt010207
PubMed: 14727840

Open original source

1997Animal research

Amylin's pramlintide best of bad bunch of diabetes drugs.

Content-verified record concerning Pramlintide: "Amylin's pramlintide best of bad bunch of diabetes drugs." (identity confirmed; no abstract text available to excerpt.)

Source: peer_reviewed_research
DOI: 10.1038/nbt1097-935
PubMed: 9335036

Open original source

2020Animal research

The effect of pramlintide, an antidiabetic amylin analogue, on angiogenesis-related markers in vitro.

Content-verified record concerning Pramlintide: "The effect of pramlintide, an antidiabetic amylin analogue, on angiogenesis-related markers in vitro." Abstract excerpt: Irregularities of angiogenesis may participate in the pathogenesis of diabetes complications. Pramlintide is an amylin analogue administered for the treatment of type 1 and type 2 diabetes. The present investigation aimed at surveying the effect of pramlintide on angiogenesis-related markers in human umbilical vein endothelial cells (HUVECs). The proliferation of cells was assessed using 3-(4,5-di

Source: peer_reviewed_research
DOI: 10.4103/1735-5362.293510
PubMed: 33312210

Open original source

2014Animal research

Expression, purification, and biological activity of the recombinant pramlintide precursor.

Content-verified record concerning Pramlintide: "Expression, purification, and biological activity of the recombinant pramlintide precursor." Abstract excerpt: Pramlintide is an artificially designed protein which has the same function as amylin in human body. This protein is extremely difficult to synthesize through prokaryotic expression method because of its two essential active sites, intrachain disulfide bond and C-terminal amide group. Since α-amidating monooxygenase is widely distributed in human and animal, it is possible to use pramlintide

Source: peer_reviewed_research
DOI: 10.1007/s00253-014-5699-2
PubMed: 24728756

Open original source

1999Animal research

The effect of pramlintide (amylin analogue) treatment on bone metabolism and bone density in patients with type 1 diabetes mellitus.

Content-verified record concerning Pramlintide: "The effect of pramlintide (amylin analogue) treatment on bone metabolism and bone density in patients with type 1 diabetes mellitus." Abstract excerpt: Amylin is a 37-amino-acid peptide related to CGRP and calcitonin. It is co-secreted with insulin from pancreatic beta-cells. Amylin is deficient with type 1 diabetes mellitus. To study the in vivo effects of amylin in humans, diabetic patients are an adequate model of chronic amylin deficiency. We investigated the effect of a 12 months pramlintide therapy (amylin analogue) on bone metabolism in pa

Source: peer_reviewed_research
DOI: 10.1055/s-2007-978777
PubMed: 10494873

Open original source

2025Animal research

Central pramlintide administration potently suppresses operant responding for sucrose and locomotor activity in male rats.

Content-verified record concerning Pramlintide: "Central pramlintide administration potently suppresses operant responding for sucrose and locomotor activity in male rats." Abstract excerpt: Amylin is a feeding-suppressive hormone which acts centrally in the control of energy balance. Some evidence suggests it reduces motivation for food rewards. Pramlintide is a synthetic amylin analog that is used clinically in the treatment of diabetes, and it also reduces feeding and weight gain. However, the mechanisms behind these pramlintide-induced reductions in feeding are unclear. Here we te

Source: peer_reviewed_research
DOI: 10.1016/j.physbeh.2025.115114
PubMed: 41022243

Open original source

2024Animal research

Chronic pramlintide decreases feeding via a reduction in meal size in male rats.

Content-verified record concerning Pramlintide: "Chronic pramlintide decreases feeding via a reduction in meal size in male rats." Abstract excerpt: Amylin, a pancreatic hormone, is well-established to suppress feeding by enhancing satiation. Pramlintide, an amylin analog that is FDA-approved for the treatment of diabetes, has also been shown to produce hypophagia. However, the behavioral mechanisms underlying the ability of pramlintide to suppress feeding are unresolved. We hypothesized that systemic pramlintide administration in rats would r

Source: peer_reviewed_research
DOI: 10.1016/j.peptides.2024.171197
PubMed: 38493922

Open original source

2019Animal research

Neuroprotective Effects of the Amylin Analog, Pramlintide, on Alzheimer's Disease Are Associated with Oxidative Stress Regulation Mechanisms.

Content-verified record concerning Pramlintide: "Neuroprotective Effects of the Amylin Analog, Pramlintide, on Alzheimer's Disease Are Associated with Oxidative Stress Regulation Mechanisms." Abstract excerpt: Administration of the recombinant analog of the pancreatic amyloid amylin, Pramlintide, has shown therapeutic benefits in aging and Alzheimer's disease (AD) models, both on cognition and amyloid-β (Aβ) pathology. However, the neuroprotective mechanisms underlying the benefits of Pramlintide remain unclear. Given the early and critical role of oxidative stress in AD pathogenesis and the

Source: peer_reviewed_research
DOI: 10.3233/jad-180421
PubMed: 30958347

Open original source

2021Animal research

ADO09, a co-formulation of the amylin analogue pramlintide and the insulin analogue A21G, lowers postprandial blood glucose versus insulin lispro in type 1 diabetes.

Content-verified record concerning Pramlintide: "ADO09, a co-formulation of the amylin analogue pramlintide and the insulin analogue A21G, lowers postprandial blood glucose versus insulin lispro in type 1 diabetes." Abstract excerpt: To compare the safety, pharmacokinetics and pharmacodynamics of ADO09 with insulin lispro (Lispro) and separate subcutaneous injections of human insulin and pramlintide (Ins&Pram) in 24 subjects with type 1 diabetes. At three dosing visits, participants received single doses of ADO09, Ins&Pram or Lispro immediately before eating a standardized mixed meal together with 1 g of acetaminophen, which w

Source: peer_reviewed_research
DOI: 10.1111/dom.14302
PubMed: 33336850

Open original source

2014Animal research

Neuroprotective effects of the amylin analogue pramlintide on Alzheimer's disease pathogenesis and cognition.

Content-verified record concerning Pramlintide: "Neuroprotective effects of the amylin analogue pramlintide on Alzheimer's disease pathogenesis and cognition." Abstract excerpt: Amylin is a metabolic peptide hormone that is co-secreted with insulin from beta cells in the pancreas and activates many of the downstream targets of insulin. To investigate the relationship between this hormone and Alzheimer's disease (AD), we measured plasma human amylin levels in 206 subjects with AD, 64 subjects with mild cognitive impairment, and 111 subjects with no cognitive impairment and

Source: peer_reviewed_research
DOI: 10.1016/j.neurobiolaging.2013.10.076
PubMed: 24239383

Open original source

2003Animal research

Ex vivo human placental transfer of the peptides pramlintide and exenatide (synthetic exendin-4).

Content-verified record concerning Pramlintide: "Ex vivo human placental transfer of the peptides pramlintide and exenatide (synthetic exendin-4)." Abstract excerpt: Two peptides, pramlintide (37 amino acids), an analog of human amylin, and exenatide, synthetic exendin-4 (39 amino acids), are both in late-stage clinical development as potential new treatments for people with diabetes. Both are potential long-term treatments, and there is the likelihood that some women will become pregnant while using one of these peptide therapies. Therefore, it was important

Source: peer_reviewed_research
DOI: 10.1191/0960327103ht402oa
PubMed: 14992323

Open original source

2024Animal research

Pramlintide an Adjunct to Insulin Therapy: Challenges and Recent Progress in Delivery.

Content-verified record concerning Pramlintide: "Pramlintide an Adjunct to Insulin Therapy: Challenges and Recent Progress in Delivery." Abstract excerpt: Dysregulation of various glucoregulatory hormones lead to failure of insulin monotherapy in patients with diabetes mellitus due to various reasons, including severe hypoglycemia, glycemic hypervariability, and an increased risk of microvascular complications. However, pramlintide as an adjunct to insulin therapy enhances glucagon suppression and thereby offers improved glycemic control. Clinical s

Source: peer_reviewed_research
DOI: 10.1124/jpet.123.001679
PubMed: 37863489

Open original source

2008Animal research

A biophysical characterization of the peptide drug pramlintide (AC137) using empirical phase diagrams.

Content-verified record concerning Pramlintide: "A biophysical characterization of the peptide drug pramlintide (AC137) using empirical phase diagrams." Abstract excerpt: AC137 (pramlintide) is a 37-residue peptide analogue of the hormone amylin. Pramlintide has been studied as an adjunct antihyperglycemic treatment for patients with type 2 or type 1 diabetes who use insulin. This study took an empirical phase diagram (EPD) approach to obtain information about the structural stability of this peptide by compiling thermal perturbation data acquired from multiple spe

Source: peer_reviewed_research
DOI: 10.1002/jps.21197
PubMed: 17879973

Open original source

2021Animal research

Alleviating carbohydrate counting with a FiASP-plus-pramlintide closed-loop delivery system (artificial pancreas): Feasibility and pilot studies.

Content-verified record concerning Pramlintide: "Alleviating carbohydrate counting with a FiASP-plus-pramlintide closed-loop delivery system (artificial pancreas): Feasibility and pilot studies." Abstract excerpt: To assess whether a FiASP-and-pramlintide closed-loop system has the potential to replace carbohydrate counting with a simple meal announcement (SMA) strategy (meal priming bolus without carbohydrate counting) without degrading glycaemic control compared with a FiASP closed-loop system. We conducted a 24-hour feasibility study comparing a FiASP system with full carbohydrate counting (FCC) with a F

Source: peer_reviewed_research
DOI: 10.1111/dom.14447
PubMed: 34047449

Open original source

2022Animal research

Pramlintide: An Amylin Analogue Protects Endothelial Cells against Oxidative Stress through Regulating Oxidative Markers and NF-κb Expression.

Content-verified record concerning Pramlintide: "Pramlintide: An Amylin Analogue Protects Endothelial Cells against Oxidative Stress through Regulating Oxidative Markers and NF-κb Expression." Abstract excerpt: Oxidative stress has a prominent role in the pathogenesis of diabetes complications. Pramlintide is an injectional amylin analogue used for the treatment of type 1 and type 2 diabetic patients. The present investigation evaluated the effect of pramlintide against oxidative damage induced by hydrogen peroxide (H 2 O 2 ) in human umbilical vein endothelial cells (HUVECs). Cell viability was assessed

Source: peer_reviewed_research
DOI: 10.4103/ijpvm.ijpvm_425_20
PubMed: 35392304

Open original source

2018Animal research

Pramlintide regulation of extracellular matrix (ECM) and apoptosis through mitochondrial-dependent pathways in human nucleus pulposus cells.

Content-verified record concerning Pramlintide: "Pramlintide regulation of extracellular matrix (ECM) and apoptosis through mitochondrial-dependent pathways in human nucleus pulposus cells." Abstract excerpt: Pramlintide, an approved analog of amylin, is responsible for regulating the physiology of energy homeostasis. The goals of this study were to investigate the roles of pramlintide in the regulation of cell survival and matrix metabolism, and further explore their underlying mechanisms, in human nucleus pulposus (NP) cells. NP cells were treated with different concentrations of pramlintide in normo

Source: peer_reviewed_research
DOI: 10.1177/0394632017747500
PubMed: 29256292

Open original source

2007Animal research

Assessing treatment satisfaction in patients treated with pramlintide as an adjunct to insulin therapy.

Content-verified record concerning Pramlintide: "Assessing treatment satisfaction in patients treated with pramlintide as an adjunct to insulin therapy." Abstract excerpt: This study was designed to assess treatment satisfaction in patients using pramlintide who had not previously achieved glycemic targets with insulin therapy alone. Assessment included the association between treatment satisfaction and clinical outcomes (changes in post-prandial glucose [PPG], glycosylated hemoglobin [HbA(1c)], weight, and insulin requirements). In this open-label study 240 partici

Source: peer_reviewed_research
DOI: 10.1185/030079907x210804
PubMed: 17624233

Open original source

2018Animal research

Pramlintide, an antidiabetic, is antineoplastic in colorectal cancer and synergizes with conventional chemotherapy.

Content-verified record concerning Pramlintide: "Pramlintide, an antidiabetic, is antineoplastic in colorectal cancer and synergizes with conventional chemotherapy." Abstract excerpt: Approximately 90% of patients with metastatic colorectal cancer fail therapy mainly due to resistance. Taking advantage of currently approved agents for treatment of disease conditions other than cancer for the identification of new adjuvant anticancer therapies is highly encouraged. Pramlintide is a parenteral antidiabetic agent that is currently approved for treatment of types 1 and 2 diabetes m

Source: peer_reviewed_research
DOI: 10.2147/cpaa.s153780
PubMed: 29551915

Open original source

2016Animal research

Synthesis and amylin receptor activity of glycomimetics of pramlintide using click chemistry.

Content-verified record concerning Pramlintide: "Synthesis and amylin receptor activity of glycomimetics of pramlintide using click chemistry." Abstract excerpt: Pramlintide (Symlin®), a synthetic analogue of the neuroendocrine hormone amylin, is devoid of the tendency to form cytotoxic amyloid fibrils and is currently used in patients with type I and type II diabetes mellitus as an adjunctive therapy with insulin or insulin analogues. As part of an on-going search for a pramlintide analogue with improved pharmacokinetic properties, we herein report t

Source: peer_reviewed_research
DOI: 10.1039/c6ob00850j
PubMed: 27139251

Open original source

2018Animal research

Pramlintide: The Effects of a Single Drug Injection on Blood Phosphatidylcholine Profile for Alzheimer's Disease.

Content-verified record concerning Pramlintide: "Pramlintide: The Effects of a Single Drug Injection on Blood Phosphatidylcholine Profile for Alzheimer's Disease." Abstract excerpt: Studies suggest that a single injection of pramlintide, an amylin analog, induces changes in Alzheimer's disease (AD) biomarkers in the blood of AD mouse models and AD patients. The aim of this study was to examine whether a pramlintide challenge combined with a phosphatidylcholine (PC) profile diagnoses of AD and mild cognitive impairment (MCI) better than PC alone. Non-diabetic subjects with cog

Source: peer_reviewed_research
DOI: 10.3233/jad-170948
PubMed: 29480193

Open original source

2020Animal research

A co-formulation of supramolecularly stabilized insulin and pramlintide enhances mealtime glucagon suppression in diabetic pigs.

Content-verified record concerning Pramlintide: "A co-formulation of supramolecularly stabilized insulin and pramlintide enhances mealtime glucagon suppression in diabetic pigs." Abstract excerpt: Treatment of patients with diabetes with insulin and pramlintide (an amylin analogue) is more effective than treatment with insulin only. However, because mixtures of insulin and pramlintide are unstable and have to be injected separately, amylin analogues are only used by 1.5% of people with diabetes needing rapid-acting insulin. Here, we show that the supramolecular modification of insulin and p

Source: peer_reviewed_research
DOI: 10.1038/s41551-020-0555-4
PubMed: 32393892

Open original source

2017Animal research

Pramlintide Antagonizes Beta Amyloid (Aβ)- and Human Amylin-Induced Depression of Hippocampal Long-Term Potentiation.

Content-verified record concerning Pramlintide: "Pramlintide Antagonizes Beta Amyloid (Aβ)- and Human Amylin-Induced Depression of Hippocampal Long-Term Potentiation." Abstract excerpt: Accumulation of amyloid-β peptide (Aβ) is a pathological hallmark of Alzheimer's disease (AD). We have previously demonstrated that electrophysiological and neurotoxic effects of Aβ and human amylin are expressed via the amylin receptor. Recently, pramlintide, a synthetic analog of amylin, has been reported to improve cognitive function in transgenic AD mouse models. In this stud

Source: peer_reviewed_research
DOI: 10.1007/s12035-016-9684-x
PubMed: 26768593

Open original source

2010Animal research

Dose accuracy and injection force of disposable pens delivering pramlintide for the treatment of diabetes.

Content-verified record concerning Pramlintide: "Dose accuracy and injection force of disposable pens delivering pramlintide for the treatment of diabetes." Abstract excerpt: The pen injection format, typically used for insulin administration, has been adapted for the injectable, noninsulin diabetes therapy pramlintide. Administered before major meals, pramlintide therapy requires two to four injections/day in addition to the patients' usual insulin injections. The dose accuracy and injection force was determined for the 60 and 120 µg pramlintide pens. Dose accura

Source: peer_reviewed_research
DOI: 10.1177/193229681000400618
PubMed: 21129339

Open original source

2011Animal research

Pramlintide and the treatment of diabetes: a review of the data since its introduction.

Content-verified record concerning Pramlintide: "Pramlintide and the treatment of diabetes: a review of the data since its introduction." Abstract excerpt: Postprandial glucose excursions negatively affect glycemic control and markers of cardiovascular health. Pramlintide, an amylinomimetic, is approved for treatment of elevated postprandial glucose levels in type 1 and type 2 diabetes mellitus. A literature search of PubMed was conducted to locate articles (up to January 2011) pertaining to original preclinical and clinical research and reviews of a

Source: peer_reviewed_research
DOI: 10.1517/14656566.2011.581663
PubMed: 21564002

Open original source

2018Animal research

Physico-chemical properties of co-formulated fast-acting insulin with pramlintide.

Content-verified record concerning Pramlintide: "Physico-chemical properties of co-formulated fast-acting insulin with pramlintide." Abstract excerpt: Since the discovery of amylin its use has been discouraged by the inadequacy of the protocol involving multiple injections in addition to insulin. We aimed here to develop a combined fixed-dose formulation of pramlintide with fast-acting insulin. We have investigated the compatibility of regular and fast-acting insulin analogues (Aspart, Asp B28 , and LisPro, Lys B28 Pro B29 ) with the amylin anal

Source: peer_reviewed_research
DOI: 10.1016/j.ijpharm.2018.06.039
PubMed: 29928940

Open original source

2008Animal research

Pramlintide in the treatment of diabetes mellitus.

Content-verified record concerning Pramlintide: "Pramlintide in the treatment of diabetes mellitus." Abstract excerpt: Pramlintide, the first member of a new class of drugs for the treatment of insulin-using patients with type 2 or type 1 diabetes mellitus, is an analog of the peptide hormone amylin. Amylin is co-secreted with insulin from pancreatic beta cells and acts centrally to slow gastric emptying, suppress postprandial glucagon secretion, and decrease food intake. These actions complement those of insulin

Source: peer_reviewed_research
DOI: 10.2165/0063030-200822060-00004
PubMed: 18998755

Open original source

1998Animal research

Isolation and identification of peptide degradation products of heat stressed pramlintide injection drug product.

Content-verified record concerning Pramlintide: "Isolation and identification of peptide degradation products of heat stressed pramlintide injection drug product." Abstract excerpt: This report summarizes the identification of nine deamidation and four hydrolysis products from a sample of pramlintide injection final drug product that was subjected to stress at 40 degrees C for 45 days. The pramlintide degradation products were isolated by strong cation exchange HPLC followed by reversed-phase HPLC. Subsequent to isolation, the molecular weight of each component was determined

Source: peer_reviewed_research
DOI: 10.1023/a:1011934829263
PubMed: 9587964

Open original source

2004Animal research

Pramlintide for the treatment of insulin-requiring diabetes mellitus: rationale and review of clinical data.

Content-verified record concerning Pramlintide: "Pramlintide for the treatment of insulin-requiring diabetes mellitus: rationale and review of clinical data." Abstract excerpt: Despite a number of incremental, beneficial improvements in diabetes mellitus therapy over the past few decades, the fundamental challenge of replicating the physiological entry into, and uptake of glucose from, the circulation remains unresolved. Pramlintide is an analogue of the beta-cell hormone amylin that simulates its important glucoregulatory actions. In humans, pramlintide slows gastric em

Source: peer_reviewed_research
DOI: 10.2165/00003495-200464130-00003
PubMed: 15212559

Open original source

1997Animal research

Amylin and glycaemic regulation: a possible role for the human amylin analogue pramlintide.

Content-verified record concerning Pramlintide: "Amylin and glycaemic regulation: a possible role for the human amylin analogue pramlintide." Abstract excerpt: Clinical studies with the human amylin analogue, pramlintide, suggest that it may help to improve glycaemic control in patients with diabetes mellitus using insulin. This has been demonstrated by reductions in postprandial glycaemic excursion, 24-h glucose profile and serum fructosamine concentrations following administration of pramlintide for periods of up to 28 days in patients with Type 1 diab

Source: peer_reviewed_research
DOI: 10.1002/(sici)1096-9136(199706)14:2+<s35::aid-dia402>3.3.co;2-#
PubMed: 9212328

Open original source

2024Animal research

Liraglutide versus pramlintide in protecting against cognitive function impairment through affecting PI3K/AKT/GSK-3β/TTBK1 pathway and decreasing Tau hyperphosphorylation in high-fat diet- streptozocin rat model.

Content-verified record concerning Pramlintide: "Liraglutide versus pramlintide in protecting against cognitive function impairment through affecting PI3K/AKT/GSK-3β/TTBK1 pathway and decreasing Tau hyperphosphorylation in high-fat diet- streptozocin rat model." Abstract excerpt: The American Diabetes Association guidelines (2021) confirmed the importance of raising public awareness of diabetes-induced cognitive impairment, highlighting the links between poor glycemic control and cognitive impairment. The characteristic brain lesions of cognitive dysfunction are neurofibrillary tangles (NFT) and senile plaques formed of amyloid-β deposition, glycogen synthase kinase

Source: peer_reviewed_research
DOI: 10.1007/s00424-024-02933-0
PubMed: 38536493

Open original source

2000Animal research

Orthogonal HPLC methods for quantitating related substances and degradation products of pramlintide.

Content-verified record concerning Pramlintide: "Orthogonal HPLC methods for quantitating related substances and degradation products of pramlintide." Abstract excerpt: Pramlintide is a 37-amino acid peptide that is being evaluated as a drug candidate for treating people with type 1 and insulin-using type 2 diabetes. Two high-performance liquid chromatography (HPLC) methods were developed for quantitating related substance impurities in pramlintide drug substance as well as degradation products of pramlintide formulated for parenteral administration. The methods

Source: peer_reviewed_research
DOI: 10.1208/pt010106
PubMed: 14727855

Open original source

2021Animal research

Ultra-Fast Insulin-Pramlintide Co-Formulation for Improved Glucose Management in Diabetic Rats.

Content-verified record concerning Pramlintide: "Ultra-Fast Insulin-Pramlintide Co-Formulation for Improved Glucose Management in Diabetic Rats." Abstract excerpt: Dual-hormone replacement therapy with insulin and amylin in patients with type 1 diabetes has the potential to improve glucose management. Unfortunately, currently available formulations require burdensome separate injections at mealtimes and have disparate pharmacokinetics that do not mimic endogenous co-secretion. Here, amphiphilic acrylamide copolymers are used to create a stable co-formulation

Source: peer_reviewed_research
DOI: 10.1002/advs.202101575
PubMed: 34499434

Open original source

2005Animal research

New drugs: exenatide, pramlintide acetate, and micafungin sodium.

Content-verified record concerning Pramlintide: "New drugs: exenatide, pramlintide acetate, and micafungin sodium." (identity confirmed; no abstract text available to excerpt.)

Source: peer_reviewed_research
DOI: 10.1331/1544345054475504
PubMed: 16128511

Open original source

2024Animal research

A temperature-responsive dual-hormone foam nanoengine improves rectal absorptivity of insulin-pramlintide for diabetes treatment.

Content-verified record concerning Pramlintide: "A temperature-responsive dual-hormone foam nanoengine improves rectal absorptivity of insulin-pramlintide for diabetes treatment." Abstract excerpt: Despite the therapeutic benefits of insulin-pramlintide dual-hormone therapy in diabetes, its application potential has been limited due to a lack of efficient delivery routes. Here, we developed a temperature-responsive dual-hormone foam nanoengine (HormFoam) and combined it with a customized spraying device to further construct an in situ foam-generating system for improving the rectal bioavaila

Source: peer_reviewed_research
DOI: 10.1126/sciadv.adn8695
PubMed: 39196940

Open original source

2001Animal research

Pramlintide (Amylin).

Content-verified record concerning Pramlintide: "Pramlintide (Amylin)." Abstract excerpt: Pramlintide is a human amylin analog, under development by Amylin (originally in collaboration with Johnson & Johnson), as an adjunct with insulin for the potential prevention of complications of type I diabetes, and as a single agent for type II diabetes [279804], [295121], [305454]. In December 2000, Amylin submitted a US NDA seeking approval to market pramlintide as an adjunctive therapy for ty

Source: peer_reviewed_research
PubMed: 11763160

Open original source

2001Animal research

Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control.

Content-verified record concerning Pramlintide: "Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control." Abstract excerpt: Destruction and dysfunction of pancreatic beta-cells, resulting in absolute and relative insulin deficiency, represent key abnormalities in the pathogenesis of type 1 and type 2 diabetes, respectively. Following the discovery of amylin, a second beta-cell hormone that is co-secreted with insulin in response to nutrient stimuli, it was realized that diabetes represents a state of bihormonal beta ce

Source: peer_reviewed_research
DOI: 10.2174/1381612013397357
PubMed: 11472273

Open original source

2012Animal research

Pramlintide: profile of an amylin analog.

Content-verified record concerning Pramlintide: "Pramlintide: profile of an amylin analog." Abstract excerpt: Amylin is a naturally occurring hormone that regulates food intake and postprandial glucose excursions. Amylin is synthesized in the β cell and cosecreted with insulin. Type 1 diabetes and insulin-requiring Type 2 diabetes are amylin-deficient as well as insulin-deficient states. Pramlintide is a synthetic amylin analog that is used for replacement therapy. Pramlintide therapy slows diabetes

Source: peer_reviewed_research
DOI: 10.1586/eem.12.50
PubMed: 30754127

Open original source

2025Animal research

Intranasal pramlintide matches intraperitoneal effects on food intake and gastric emptying in mice.

Content-verified record concerning Pramlintide: "Intranasal pramlintide matches intraperitoneal effects on food intake and gastric emptying in mice." Abstract excerpt: Pramlintide is an amylin analog developed as a complementary treatment for diabetes. However, it requires several subcutaneous injections, reducing patients' adherence. Since the intranasal route might be an alternative for drug administration, we evaluated whether intranasal pramlintide treatment exerts comparable actions with intraperitoneal administration. Adult male Swiss mice were submitted t

Source: peer_reviewed_research
DOI: 10.1007/s12020-025-04220-z
PubMed: 40169506

Open original source

2021Animal research

Effects of pramlintide on energy intake and food preference in rats given a choice diet.

Content-verified record concerning Pramlintide: "Effects of pramlintide on energy intake and food preference in rats given a choice diet." Abstract excerpt: Amylin is a peptide hormone involved in the control of energy balance, making the amylin system a potential target for pharmacotherapies to treat obesity. Pramlintide, an amylin analogue, is an FDA-approved medication for the treatment of diabetes that also has food intake- and body weight-suppressive effects. However, it is unknown whether pramlintide may preferentially reduce intake of highly pa

Source: peer_reviewed_research
DOI: 10.1016/j.physbeh.2021.113541
PubMed: 34332974

Open original source

2015Animal research

Analysis of the ability of pramlintide to inhibit amyloid formation by human islet amyloid polypeptide reveals a balance between optimal recognition and reduced amyloidogenicity.

Content-verified record concerning Pramlintide: "Analysis of the ability of pramlintide to inhibit amyloid formation by human islet amyloid polypeptide reveals a balance between optimal recognition and reduced amyloidogenicity." Abstract excerpt: The hormone human islet amyloid polypeptide (hIAPP or amylin) plays a role in glucose metabolism, but forms amyloid in the pancreas in type 2 diabetes (T2D) and is associated with β-cell death and dysfunction in the disease. Inhibitors of islet amyloid have therapeutic potential; however, there are no clinically approved inhibitors, and the mode of action of existing inhibitors is not well u

Source: peer_reviewed_research
DOI: 10.1021/acs.biochem.5b00567
PubMed: 26407043

Open original source

2014Animal research

A model of glucose-insulin-pramlintide pharmacokinetics and pharmacodynamics in type I diabetes.

Content-verified record concerning Pramlintide: "A model of glucose-insulin-pramlintide pharmacokinetics and pharmacodynamics in type I diabetes." Abstract excerpt: Type 1 diabetes mellitus (T1DM) complications are significantly reduced when normoglycemic levels are maintained via intensive therapy. The artificial pancreas is designed for intensive glycemic control; however, large postprandial excursions after a meal result in poor glucose regulation. Pramlintide, a synthetic analog of the hormone amylin, reduces the severity of postprandial excursions by red

Source: peer_reviewed_research
DOI: 10.1177/1932296813517323
PubMed: 24876617

Open original source

2020Animal research

Amylin and pramlintide modulate γ-secretase level and APP processing in lipid rafts.

Content-verified record concerning Pramlintide: "Amylin and pramlintide modulate γ-secretase level and APP processing in lipid rafts." Abstract excerpt: A major characteristic of Alzheimer's disease (AD) is the accumulation of misfolded amyloid-β (Aβ) peptide. Several studies linked AD with type 2 diabetes due to similarities between Aβ and human amylin. This study investigates the effect of amylin and pramlintide on Aβ pathogenesis and the predisposing molecular mechanism(s) behind the observed effects in TgSwDI mouse, a c

Source: peer_reviewed_research
DOI: 10.1038/s41598-020-60664-5
PubMed: 32111883

Open original source

2013Animal research

Glycosylation of pramlintide: synthetic glycopeptides that display in vitro and in vivo activities as amylin receptor agonists.

Content-verified record concerning Pramlintide: "Glycosylation of pramlintide: synthetic glycopeptides that display in vitro and in vivo activities as amylin receptor agonists." (identity confirmed; no abstract text available to excerpt.)

Source: peer_reviewed_research
DOI: 10.1002/chem.201303303
PubMed: 24123422

Open original source

1998Animal research

Nephrectomy decreases amylin and pramlintide clearance in rats.

Content-verified record concerning Pramlintide: "Nephrectomy decreases amylin and pramlintide clearance in rats." Abstract excerpt: Amylin is a 37 amino acid hormone, co-secreted with insulin from the pancreatic beta-cell in response to nutrient stimuli. Because the human amylin analog, pramlintide, is being tested in patients with diabetes mellitus, a known risk factor for nephropathy, we examined the role of the kidney on amylin and pramlintide metabolism and action in functionally nephrectomized rats. Nephrectomy markedly a

Source: peer_reviewed_research
DOI: 10.1055/s-2007-978923
PubMed: 9761382

Open original source

2014Animal research

Activity of pramlintide, rat and human amylin but not Aβ1-42 at human amylin receptors.

Content-verified record concerning Pramlintide: "Activity of pramlintide, rat and human amylin but not Aβ1-42 at human amylin receptors." Abstract excerpt: Amylin is a neuroendocrine hormone involved in glucose regulation. An amylin analog, pramlintide, is used to treat insulin-requiring diabetes. Its anorexigenic actions give it potential as an obesity treatment. There are 3 amylin receptors (AMY1, AMY2, AMY3), comprising the calcitonin receptor and receptor activity-modifying proteins 1, 2, and 3, respectively. The pharmacology of pramlintide at ea

Source: peer_reviewed_research
DOI: 10.1210/en.2013-1658
PubMed: 24169554

Open original source

2010Animal research

The role of pramlintide for weight loss.

Content-verified record concerning Pramlintide: "The role of pramlintide for weight loss." Abstract excerpt: To evaluate the weight-loss effects of pramlintide. A literature search was conducted in MEDLINE (1950-October week 4, 2009), International Pharmaceutical Abstracts (1970-October 2009), and Evidence Based Medicine Database (1991-2009 week 44) to identify relevant publications. Key words searched included pramlintide, weight loss, obesity, and overweight. Additional data sources were obtained throu

Source: peer_reviewed_research
DOI: 10.1345/aph.1m210
PubMed: 20164472

Open original source

2018Animal research

Study of forced degradation behavior of pramlintide acetate by HPLC and LC-MS.

Content-verified record concerning Pramlintide: "Study of forced degradation behavior of pramlintide acetate by HPLC and LC-MS." Abstract excerpt: Pramlintide acetate (Symlin ® ), a synthetic analogue of the human hormone amylin. It was approved in March 2005 as a subcutaneous injection for the adjunctive treatment of patients who have type 1 or 2 diabetes mellitus. The objective of current investigation was to study the degradation behavior of pramlintide acetate under different ICH recommended stress conditions by HPLC and LC-MS. Pram

Source: peer_reviewed_research
DOI: 10.1016/j.jfda.2017.07.009
PubMed: 29389581

Open original source

2023Animal research

Contraction of human brain vascular pericytes in response to islet amyloid polypeptide is reversed by pramlintide.

Content-verified record concerning Pramlintide: "Contraction of human brain vascular pericytes in response to islet amyloid polypeptide is reversed by pramlintide." Abstract excerpt: The islet amyloid polypeptide (IAPP), a pancreas-produced peptide, has beneficial functions in its monomeric form. However, IAPP aggregates, related to type 2 diabetes mellitus (T2DM), are toxic not only for the pancreas, but also for the brain. In the latter, IAPP is often found in vessels, where it is highly toxic for pericytes, mural cells that have contractile properties and regulate capillary

Source: peer_reviewed_research
DOI: 10.1186/s13041-023-01013-1
PubMed: 36793056

Open original source

2017Animal research

Be positive: optimizing pramlintide from microcanonical analysis of amylin isoforms.

Content-verified record concerning Pramlintide: "Be positive: optimizing pramlintide from microcanonical analysis of amylin isoforms." Abstract excerpt: Amylin, or human islet amyloid polypeptide (hIAPP), is a 37-residue hormone synergistic to insulin and co-secreted with it by β-cells in the pancreas. The deposition of its cytotoxic amyloid fibrils is strongly related to the progression of Type II diabetes (T2D) and islet graft failures. Notably, isoforms from some mammalian species, such as rats (rIAPP) and porcine (pIAPP), present a few k

Source: peer_reviewed_research
DOI: 10.1039/c7cp04074a
PubMed: 28905065

Open original source

2012Animal research

[D-Leu-4]-OB3, a synthetic peptide amide with leptin-like activity, augments the effects of orally delivered exenatide and pramlintide acetate on energy balance and glycemic control in insulin-resistant male C57BLK/6-m db/db mice.

Content-verified record concerning Pramlintide: "[D-Leu-4]-OB3, a synthetic peptide amide with leptin-like activity, augments the effects of orally delivered exenatide and pramlintide acetate on energy balance and glycemic control in insulin-resistant male C57BLK/6-m db/db mice." Abstract excerpt: The escalation predicted for the incidence of both type 2 diabetes mellitus and obesity has prompted investigators to search for additional pharmacotherapeutic approaches to their treatment. Two of these approaches, combination pharmacotherapy and utilization of leptin-related bioactive synthetic peptides as anti-diabetes/anti-obesity agents, were used in the present study. Exenatide or pramlintid

Source: peer_reviewed_research
DOI: 10.1016/j.regpep.2012.08.006
PubMed: 22960403

Open original source

2000Animal research

Pramlintide injection drug product robustness studies.

Content-verified record concerning Pramlintide: "Pramlintide injection drug product robustness studies." Abstract excerpt: The article examines the effects of temperature excursions and actual dose withdrawal on the quality of pramlintide injection, a multidose liquid parenteral formulation. Studies were designed to demonstrate product robustness under conditions that may occur during patient use. Pramlintide %Purity was determined by two high-performance liquid chromatography (HPLC) methods, a reversed-phase (RP-HPLC

Source: peer_reviewed_research
DOI: 10.1208/pt010208
PubMed: 14727841

Open original source

1999Laboratory research

Isolation and identification of cyclic imide and deamidation products in heat stressed pramlintide injection drug product.

Content-verified record concerning Pramlintide: "Isolation and identification of cyclic imide and deamidation products in heat stressed pramlintide injection drug product." Abstract excerpt: This report summarizes the identification of six cyclic imide [Asu] and two deamidation products from a sample of pramlintide final drug product that had been stressed at 40 degrees C for 45 days. The pramlintide degradation products were isolated by cation exchange high-performance liquid chromatography (HPLC) followed by reversed-phase HPLC. The isolated components were characterized by mass spe

Source: peer_reviewed_research
DOI: 10.1016/s0731-7085(99)00075-8
PubMed: 10701984

Open original source

2011Laboratory research

Primer on pramlintide, an amylin analog.

Content-verified record concerning Pramlintide: "Primer on pramlintide, an amylin analog." Abstract excerpt: Pramlintide is an injectable synthetic analog of human amylin. It is indicated for patients with type 1 or type 2 diabetes who are taking mealtime insulin but have been unable to achieve desired glucose targets. Pramlintide decreases postprandial glucose by lowering inappropriate postmeal glucagon secretion, slowing gastric emptying, and increasing satiety. As such, pramlintide targets several of

Source: peer_reviewed_research
DOI: 10.1177/0145721711403011
PubMed: 21471470

Open original source

2017Laboratory research

Zn(II) - pramlintide: Stability, binding sites and unexpected aggregation.

Content-verified record concerning Pramlintide: "Zn(II) - pramlintide: Stability, binding sites and unexpected aggregation." Abstract excerpt: Pramlintide is an antidiabetic drug which mimics amylin - a small peptide co-secreted from pancreatic β-cells together with insulin, one of the hallmarks of type 2 diabetes. In the course of the disease, amylin misfolds into small oligomers or to an aggregated β-sheet amyloid fiber. The misfolding mechanism is not yet quite understood, but it is clear that zinc ions play an important r

Source: peer_reviewed_research
DOI: 10.1016/j.jinorgbio.2017.06.008
PubMed: 28672144

Open original source

2016Laboratory research

Amyloidogenesis of the amylin analogue pramlintide.

Content-verified record concerning Pramlintide: "Amyloidogenesis of the amylin analogue pramlintide." Abstract excerpt: Amylin is a pancreatic peptide hormone co-secreted along with insulin by the β-cells. It is found in amyloid deposits in both type 2 diabetic individuals and elder non-diabetic. The triple proline amylinomimetic compound (25,28,29-Pro-human amylin) named pramlintide was designed aiming to solve the solubility and amyloid characteristics of human amylin. We have found by using ion mobility sp

Source: peer_reviewed_research
DOI: 10.1016/j.bpc.2016.09.007
PubMed: 27665170

Open original source

2009Insufficient evidence

A pilot trial of pramlintide home usage in adolescents with type 1 diabetes.

Content-verified record concerning Pramlintide: "A pilot trial of pramlintide home usage in adolescents with type 1 diabetes." Abstract excerpt: The objective of this study was to evaluate the safety and efficacy of home pramlintide use in adolescents with type 1 diabetes. This was a randomized, 28-day pilot trial of pramlintide (maximum dose: 30 microg per meal) in 10 adolescents aged 13 to 17 years. End points included changes in hemoglobin A1c (HbA1c) values, body weight, and postprandial peak blood glucose levels and area under the cur

Source: peer_reviewed_research
DOI: 10.1542/peds.2008-3750
PubMed: 19858155

Open original source

1999Insufficient evidence

The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus.

Content-verified record concerning Pramlintide: "The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus." Abstract excerpt: To explore further the effects of the human amylin analog pramlintide on overall glycemic control and postprandial responses of circulating glucose, glucagon, and metabolic intermediates in type 1 diabetes mellitus, 14 male type 1 diabetic patients were examined in a double-blind, placebo-controlled, crossover study. Pramlintide (30 microg four times daily) or placebo were administered for 4 weeks

Source: peer_reviewed_research
DOI: 10.1016/s0026-0495(99)90232-9
PubMed: 10421239

Open original source

2023Insufficient evidence

A co-formulation of pramlintide and insulin A21G (ADO09) improves postprandial glucose and short-term control of mean glucose, time in range, and body weight versus insulin aspart in adults with type 1 diabetes.

Content-verified record concerning Pramlintide: "A co-formulation of pramlintide and insulin A21G (ADO09) improves postprandial glucose and short-term control of mean glucose, time in range, and body weight versus insulin aspart in adults with type 1 diabetes." Abstract excerpt: Pramlintide improves postprandial glucose but requires additional injections. We investigated the pharmacokinetics/pharmacodynamics, efficacy and safety of ADO09, pramlintide/insulin A21G co-formulation, in type 1 diabetes (T1D). This double-blinded, randomized, two-period cross-over study compared prandial administration of ADO09 or insulin aspart over 24 days in T1D using either ≤40 U bol

Source: peer_reviewed_research
DOI: 10.1111/dom.14972
PubMed: 36633505

Open original source

2007Insufficient evidence

The role of prandial pramlintide in the treatment of adolescents with type 1 diabetes.

Content-verified record concerning Pramlintide: "The role of prandial pramlintide in the treatment of adolescents with type 1 diabetes." Abstract excerpt: Pramlintide, a synthetic analog of amylin, improves postprandial hyperglycemia. We compared subcutaneous (s.c.) pramlintide injection with square wave pramlintide infusion in adolescents with type 1 diabetes (T1DM). Eight subjects with T1DM underwent two randomized studies. Subcutaneous pramlintide (dose = 5 microg/unit of insulin) bolus, was given one time and another time, the same dose was give

Source: peer_reviewed_research
DOI: 10.1203/pdr.0b013e318159af8c
PubMed: 17957149

Open original source

2007Insufficient evidence

Effect of adjunctive pramlintide treatment on treatment satisfaction in patients with type 1 diabetes.

Content-verified record concerning Pramlintide: "Effect of adjunctive pramlintide treatment on treatment satisfaction in patients with type 1 diabetes." Abstract excerpt: To assess the effect of adjunctive pramlintide treatment on treatment satisfaction in patients with type 1 diabetes treated with intensive insulin regimens. Intensively treated (multiple daily injection [MDI] or continuous subcutaneous insulin infusion [CSII] pump therapy) patients with type 1 diabetes completed a study-specific treatment satisfaction questionnaire following 29 weeks of either pla

Source: peer_reviewed_research
DOI: 10.2337/dc06-1026
PubMed: 17259483

Open original source

2015Insufficient evidence

Fixed ratio dosing of pramlintide with regular insulin before a standard meal in patients with type 1 diabetes.

Content-verified record concerning Pramlintide: "Fixed ratio dosing of pramlintide with regular insulin before a standard meal in patients with type 1 diabetes." Abstract excerpt: Amylin is co-secreted with insulin and is therefore lacking in patients with type 1 diabetes. Replacement with fixed ratio co-administration of insulin and the amylin analogue pramlintide may be superior to separate dosing. This concept was evaluated in a ratio-finding study. Patients with type 1 diabetes were enrolled in a randomized, single-masked, standard breakfast crossover study using regula

Source: peer_reviewed_research
DOI: 10.1111/dom.12504
PubMed: 26040429

Open original source

2003Insufficient evidence

Effect of pramlintide on A1C and body weight in insulin-treated African Americans and Hispanics with type 2 diabetes: a pooled post hoc analysis.

Content-verified record concerning Pramlintide: "Effect of pramlintide on A1C and body weight in insulin-treated African Americans and Hispanics with type 2 diabetes: a pooled post hoc analysis." Abstract excerpt: An unresolved problem in the management of type 2 diabetes is that improvement of glycemic control with insulin, insulin secretagogues, and insulin sensitizers is often accompanied by undesired weight gain. This problem is of particular concern in ethnic groups with a high propensity for diabetes and obesity, such as African Americans and Hispanics. Two 1-year, randomized, double-blind, placebo-co

Source: peer_reviewed_research
DOI: 10.1016/j.metabol.2003.06.003
PubMed: 14669170

Open original source

1998Insufficient evidence

[Effects of pramlintide, an analog of amylin, on the regulation of glycemia].

Content-verified record concerning Pramlintide: "[Effects of pramlintide, an analog of amylin, on the regulation of glycemia]." (identity confirmed; no abstract text available to excerpt.)

Source: systematic_review_or_meta_analysis
PubMed: 9773629

Open original source

2021Insufficient evidence

Amylin Analog Pramlintide Induces Migraine-like Attacks in Patients.

Content-verified record concerning Pramlintide: "Amylin Analog Pramlintide Induces Migraine-like Attacks in Patients." Abstract excerpt: Migraine is a prevalent and disabling neurological disease. Its genesis is poorly understood, and there remains unmet clinical need. We aimed to identify mechanisms and thus novel therapeutic targets for migraine using human models of migraine and translational models in animals, with emphasis on amylin, a close relative of calcitonin gene-related peptide (CGRP). Thirty-six migraine without aura p

Source: peer_reviewed_research
DOI: 10.1002/ana.26072
PubMed: 33772845

Open original source

2006Insufficient evidence

Exenatide and pramlintide: new glucose-lowering agents for treating diabetes mellitus.

Content-verified record concerning Pramlintide: "Exenatide and pramlintide: new glucose-lowering agents for treating diabetes mellitus." Abstract excerpt: Insulin is not the only hormone that regulates plasma glucose levels. Glucagon-like peptide 1 (GLP-1), produced in the small intestine, and amylin, produced by beta cells in the pancreas, also have glucose-lowering effects. Synthetic analogues of these hormones are now available for clinical use.

Source: systematic_review_or_meta_analysis
DOI: 10.3949/ccjm.73.5.477
PubMed: 16708716

Open original source

2022Insufficient evidence

Zn(II) binding to pramlintide results in a structural kink, fibril formation and antifungal activity.

Content-verified record concerning Pramlintide: "Zn(II) binding to pramlintide results in a structural kink, fibril formation and antifungal activity." Abstract excerpt: The antimicrobial properties of amylin, a 37-amino acid peptide hormone, co-secreted with insulin from the pancreas, are far less known than its antidiabetic function. We provide insight into the bioinorganic chemistry of amylin analogues, showing that the coordination of zinc(II) enhances the antifungal properties of pramlintide, a non-fibrillating therapeutic analogue of amylin. Zinc binds to th

Source: peer_reviewed_research
DOI: 10.1038/s41598-022-24968-y
PubMed: 36446825

Open original source

2025Insufficient evidence

In silico evaluation of pramlintide dosing algorithms in artificial pancreas systems.

Content-verified record concerning Pramlintide: "In silico evaluation of pramlintide dosing algorithms in artificial pancreas systems." Abstract excerpt: Pramlintide's capability to delay gastric emptying has motivated its use in artificial pancreas systems, accompanying insulin as a control action. Due to the scarcity of pramlintide simulation models in the literature, in silico testing of insulin-plus-pramlintide strategies is not widely used. This work incorporates a recent pramlintide pharmacokinetics/pharmacodynamics model into the T1DM UVA/Pa

Source: peer_reviewed_research
DOI: 10.1016/j.compbiomed.2025.110447
PubMed: 40513482

Open original source

2009Insufficient evidence

Continuous subcutaneous pramlintide infusion therapy in patients with type 1 diabetes: observations from a pilot study.

Content-verified record concerning Pramlintide: "Continuous subcutaneous pramlintide infusion therapy in patients with type 1 diabetes: observations from a pilot study." Abstract excerpt: To investigate the efficacy and safety of continuous (basal-bolus) subcutaneous pramlintide infusion (CSPI) in patients with type 1 diabetes mellitus. A 16-week, open-label, single-arm pilot study enrolled 11 patients (mean +/- SD values: age, 39.9 +/- 4.0 years; hemoglobin A1c, 8.20% +/- 0.60%; weight, 92.3 +/- 18.4 kg; body mass index, 29.7 +/- 5.1 kg/m2) with longterm type 1 diabetes mellitus (

Source: peer_reviewed_research
DOI: 10.4158/ep09044.orr1
PubMed: 19546056

Open original source

2006Insufficient evidence

Adjunctive therapy with pramlintide in patients with type 1 or type 2 diabetes mellitus.

Content-verified record concerning Pramlintide: "Adjunctive therapy with pramlintide in patients with type 1 or type 2 diabetes mellitus." Abstract excerpt: Uncontrolled diabetes mellitus is associated with both microvascular and macrovascular complications. Despite an array of treatment options available, achievement of euglycemia in most patients with diabetes is still lacking. Pramlintide acetate, a synthetic analog of the human hormone amylin and belonging to a new class of agents, was approved in March 2005 as adjunctive treatment in patients wit

Source: peer_reviewed_research
DOI: 10.1592/phco.26.11.1626
PubMed: 17064208

Open original source

2005Insufficient evidence

Adjunctive therapy with pramlintide lowers HbA1c without concomitant weight gain and increased risk of severe hypoglycemia in patients with type 1 diabetes approaching glycemic targets.

Content-verified record concerning Pramlintide: "Adjunctive therapy with pramlintide lowers HbA1c without concomitant weight gain and increased risk of severe hypoglycemia in patients with type 1 diabetes approaching glycemic targets." Abstract excerpt: In long-term clinical trials in patients with type 1 diabetes spanning a wide range of HbA1c, addition of pramlintide to existing insulin regimens led to reductions in HbA1c that were accompanied by weight loss and no increase in overall severe hypoglycemia event rates. Given that weight gain and increased hypoglycemia risk contribute to the difficulty of attaining HbA1c targets (<7 %), the que

Source: peer_reviewed_research
DOI: 10.1055/s-2005-837662
PubMed: 15891954

Open original source

2002Insufficient evidence

The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes.

Content-verified record concerning Pramlintide: "The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes." Abstract excerpt: Mealtime amylin replacement with the human amylin analog pramlintide as an adjunct to insulin therapy improves postprandial glycemia and long-term glycemic control in type 1 diabetes. Preclinical animal studies indicate that these complementary effects may result from at least 2 independent mechanisms: a slowing of nutrient delivery to the small intestine and a suppression of nutrient-stimulated g

Source: peer_reviewed_research
DOI: 10.1053/meta.2002.32022
PubMed: 11979398

Open original source

2002Insufficient evidence

The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus.

Content-verified record concerning Pramlintide: "The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus." Abstract excerpt: Amylin is a second beta-cell hormone that is normally co-secreted with insulin in response to meals; it complements the effects of insulin in postprandial glucose control, in part by suppressing glucagon secretion. In patients with type 2 diabetes, mealtime administration of the human amylin analog pramlintide markedly improves postprandial glucose excursions. The aim of this study was to examine

Source: peer_reviewed_research
DOI: 10.1055/s-2002-34790
PubMed: 12384827

Open original source

2009Insufficient evidence

Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy.

Content-verified record concerning Pramlintide: "Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy." Abstract excerpt: The neurohormonal control of body weight involves a complex interplay between long-term adiposity signals (e.g., leptin), and short-term satiation signals (e.g., amylin). In diet-induced obese (DIO) rodents, amylin/leptin combination treatment led to marked, synergistic, fat-specific weight loss. To evaluate the weight-lowering effect of combined amylin/leptin agonism (with pramlintide/metreleptin

Source: peer_reviewed_research
DOI: 10.1038/oby.2009.184
PubMed: 19521351

Open original source

2024Insufficient evidence

ADO09, a co-formulation of pramlintide and insulin A21G, lowers body weight versus insulin lispro in type 1 diabetes.

Content-verified record concerning Pramlintide: "ADO09, a co-formulation of pramlintide and insulin A21G, lowers body weight versus insulin lispro in type 1 diabetes." Abstract excerpt: To study safety, efficacy and weight loss with ADO09, a co-formulation of insulin A21G and pramlintide, in type 1 diabetes. A randomized, two-arm ambulatory 16-week study compared ADO09 with insulin lispro in 80 participants with type 1 diabetes. We compared changes of weight, glycated haemoglobin, glycaemic patterns during continuous glucose monitoring, and insulin doses at baseline and at the en

Source: peer_reviewed_research
DOI: 10.1111/dom.15827
PubMed: 39109464

Open original source

1998Insufficient evidence

The effect of single doses of pramlintide on gastric emptying of two meals in men with IDDM.

Content-verified record concerning Pramlintide: "The effect of single doses of pramlintide on gastric emptying of two meals in men with IDDM." Abstract excerpt: In a previous study we have shown that an intravenous infusion of pramlintide (an analogue of human amylin) delayed gastric emptying, but the dose of pramlintide was supraphysiological in relation to the amylin response to food in non-diabetic subjects. The purpose of this study was to examine the dose response relationship of subcutaneous injections of pramlintide on gastric emptying and to deter

Source: peer_reviewed_research
DOI: 10.1007/s001250050949
PubMed: 9628276

Open original source

1999Insufficient evidence

Effects of the amylin analogue pramlintide on hepatic glucagon responses and intermediary metabolism in Type 1 diabetic subjects.

Content-verified record concerning Pramlintide: "Effects of the amylin analogue pramlintide on hepatic glucagon responses and intermediary metabolism in Type 1 diabetic subjects." Abstract excerpt: Hepatic glycogen stores have been shown to be depleted, and glucagon stimulated hepatic glucose production reduced, in Type 1 diabetic subjects. Co-administration of amylin and insulin has been shown to replete hepatic glycogen stores in diabetic animal models. The aim of the present study was to investigate the effect of amylin replacement on hepatic glucagon responsiveness in humans. Thirteen Ty

Source: peer_reviewed_research
DOI: 10.1046/j.1464-5491.1999.00162.x
PubMed: 10547215

Open original source

2006Insufficient evidence

Diabetes basics. Exenatide and pramlintide. New meds on the block.

Content-verified record concerning Pramlintide: "Diabetes basics. Exenatide and pramlintide. New meds on the block." (identity confirmed; no abstract text available to excerpt.)

Source: peer_reviewed_research
PubMed: 16888865

Open original source

1997Insufficient evidence

Effects of 4 weeks' administration of pramlintide, a human amylin analogue, on glycaemia control in patients with IDDM: effects on plasma glucose profiles and serum fructosamine concentrations.

Content-verified record concerning Pramlintide: "Effects of 4 weeks' administration of pramlintide, a human amylin analogue, on glycaemia control in patients with IDDM: effects on plasma glucose profiles and serum fructosamine concentrations." Abstract excerpt: The effects of 4 weeks' administration of pramlintide, an analogue of the human hormone amylin, on blood glucose control in 215 patients with insulin-dependent diabetes mellitus were examined in a 4-week, randomized, double-blind, placebo-controlled, parallel-group trial. Pramlintide was administered subcutaneously prior to meals in four dosing regimens: 30 microg four times per day (breakfast, lu

Source: peer_reviewed_research
DOI: 10.1007/s001250050821
PubMed: 9389419

Open original source

1997Insufficient evidence

USAN Council. List No.392. New names. Pramlintide.

Content-verified record concerning Pramlintide: "USAN Council. List No.392. New names. Pramlintide." (identity confirmed; no abstract text available to excerpt.)

Source: peer_reviewed_research
DOI: 10.1016/s0009-9236(97)90208-3
PubMed: 9147903

Open original source

2009Insufficient evidence

Minimal reduction in insulin dosage with pramlintide therapy when pretreatment near-normal glycemia is established and square-wave meal bolus is used.

Content-verified record concerning Pramlintide: "Minimal reduction in insulin dosage with pramlintide therapy when pretreatment near-normal glycemia is established and square-wave meal bolus is used." Abstract excerpt: To evaluate the effect of near-normal glucose control before initiation of pramlintide therapy and square-wave meal bolus on self-reported hypoglycemia and the percentage change in dosing parameters after attaining the maximum pramlintide dosage. In this prospective study, insulin pump-treated patients with type 1 diabetes had insulin dosages optimally titrated on the basis of daily continuous glu

Source: peer_reviewed_research
DOI: 10.4158/ep.15.3.229
PubMed: 19364691

Open original source

2008Insufficient evidence

Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity.

Content-verified record concerning Pramlintide: "Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity." Abstract excerpt: To assess long-term weight loss efficacy and safety of pramlintide used at different dosing regimens and in conjunction with lifestyle intervention (LSI). In a 4-month, double-blind, placebo-controlled, dose-ranging study, 411 obese subjects were randomized to receive pramlintide (six arms: 120, 240, and 360 microg b.i.d. and t.i.d.) or placebo in conjunction with a structured LSI program geared t

Source: peer_reviewed_research
DOI: 10.2337/dc08-0029
PubMed: 18753666

Open original source

2008Insufficient evidence

Clinical experience with the addition of pramlintide in patients with insulin-requiring type 2 diabetes.

Content-verified record concerning Pramlintide: "Clinical experience with the addition of pramlintide in patients with insulin-requiring type 2 diabetes." (identity confirmed; no abstract text available to excerpt.)

Source: peer_reviewed_research
DOI: 10.2337/dc07-0641
PubMed: 17909093

Open original source

1997Insufficient evidence

Effects of Amylin and the Amylin Agonist Pramlintide on Glucose Metabolism

Content-verified record concerning Pramlintide: "Effects of Amylin and the Amylin Agonist Pramlintide on Glucose Metabolism" Abstract excerpt: Since the discovery of the pancreatic islet hormone amylin in 1987, its metabolic effects have been investigated in a number of studies in animals and humans. Data from some early animal studies suggested that amylin might be associated with the development of insulin resistance, but other studies found that amylin had no effect on insulin sensitivity. More recently, studies performed using the hu

Source: peer_reviewed_research
DOI: 10.1002/(sici)1096-9136(199706)14:2+<s19::aid-dia400>3.0.co;2-4
PubMed: 9212325

Open original source

2002Insufficient evidence

Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes.

Content-verified record concerning Pramlintide: "Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes." Abstract excerpt: The objective of this study was to assess the effect of mealtime amylin replacement with pramlintide on long-term glycemic and weight control in subjects with type 2 diabetes. This 52-week, randomized, placebo-controlled, multicenter, double-blind, dose-ranging study in 538 insulin-treated subjects with type 2 diabetes compared the efficacy and safety of 30-, 75-, or 150-microg doses of pramlintid

Source: peer_reviewed_research
DOI: 10.1089/15209150252924094
PubMed: 12017421

Open original source

2016Insufficient evidence

Impact of Disease Duration on the Effects of Pramlintide in Type 1 Diabetes: A Post Hoc Analysis of Three Clinical Trials.

Content-verified record concerning Pramlintide: "Impact of Disease Duration on the Effects of Pramlintide in Type 1 Diabetes: A Post Hoc Analysis of Three Clinical Trials." Abstract excerpt: Adjunctive mealtime use of the amylin analog pramlintide improves postprandial hyperglycemia in patients with type 1 diabetes. This post hoc analysis of three randomized trials evaluated whether disease duration affected responses to pramlintide. Patients received mealtime pramlintide 30 or 60 µg (n = 714) or placebo (n = 537) as an adjunct to insulin and were stratif

Source: peer_reviewed_research
DOI: 10.1007/s12325-016-0326-5
PubMed: 27071768

Open original source

2010Insufficient evidence

Efficacy and harms of the hypoglycemic agent pramlintide in diabetes mellitus.

Content-verified record concerning Pramlintide: "Efficacy and harms of the hypoglycemic agent pramlintide in diabetes mellitus." Abstract excerpt: We conducted a study to examine the efficacy, effectiveness, and harms of pramlintide as adjunct therapy in adults and children with type 1 or type 2 diabetes. We searched multiple bibliographic databases to January 2010, the US Food and Drug Administration Web site, and other sources to identify randomized controlled trials (RCTs) fulfilling inclusion criteria. Syntheses were qualitative because

Source: peer_reviewed_research
DOI: 10.1370/afm.1174
PubMed: 21060125

Open original source

2010Insufficient evidence

Enhanced weight loss following coadministration of pramlintide with sibutramine or phentermine in a multicenter trial.

Content-verified record concerning Pramlintide: "Enhanced weight loss following coadministration of pramlintide with sibutramine or phentermine in a multicenter trial." Abstract excerpt: Preclinical evidence suggests that pharmacotherapy for obesity using combinations of agents targeted at distinct regulatory pathways may produce robust additive or synergistic effects on weight loss. This randomized placebo-controlled trial examined the safety and efficacy of the amylin analogue pramlintide alone or in combination with either phentermine or sibutramine. All patients also received

Source: peer_reviewed_research
DOI: 10.1038/oby.2009.478
PubMed: 20094043

Open original source

2002Insufficient evidence

Anti-diabetogenic effect of the human amylin analogue, pramlintide, in Type 1 diabetes is not mediated by GLP-1.

Content-verified record concerning Pramlintide: "Anti-diabetogenic effect of the human amylin analogue, pramlintide, in Type 1 diabetes is not mediated by GLP-1." (identity confirmed; no abstract text available to excerpt.)

Source: peer_reviewed_research
DOI: 10.1046/j.1464-5491.2002.00657_1.x
PubMed: 12207819

Open original source

2009Insufficient evidence

Solution state structures of human pancreatic amylin and pramlintide.

Content-verified record concerning Pramlintide: "Solution state structures of human pancreatic amylin and pramlintide." Abstract excerpt: We have employed pramlintide (prAM) as a surrogate for hAM in CD and NMR studies of the conformational preferences of the N-terminal portion of the structure in media which do not provide long-lived monomeric solutions of hAM due to its rapid conversion to preamyloid beta aggregate states. Direct comparison of hAM and prAM could be made under helix-formation-favoring conditions. On the basis of CD

Source: peer_reviewed_research
DOI: 10.1093/protein/gzp029
PubMed: 19596697

Open original source

2009Insufficient evidence

Reducing postprandial hyperglycemia with adjuvant premeal pramlintide and postmeal insulin in children with type 1 diabetes mellitus.

Content-verified record concerning Pramlintide: "Reducing postprandial hyperglycemia with adjuvant premeal pramlintide and postmeal insulin in children with type 1 diabetes mellitus." Abstract excerpt: The purpose of this study was to determine the effect of adjuvant premeal pramlintide with postmeal insulin on postprandial hyperglycemia in children with type 1 diabetes mellitus (T1DM). Eight adolescents with T1DM on intensive insulin therapy participated in an open-label, non-randomized, crossover study, comparing postprandial glucose excursions in study A (prescribed insulin regimen and given

Source: peer_reviewed_research
DOI: 10.1111/j.1399-5448.2008.00490.x
PubMed: 19140902

Open original source

2013Insufficient evidence

In silico design of optimal ratio for co-administration of pramlintide and insulin in type 1 diabetes.

Content-verified record concerning Pramlintide: "In silico design of optimal ratio for co-administration of pramlintide and insulin in type 1 diabetes." Abstract excerpt: The ability to simulate in silico experiments is crucial for fast and cost-effective preliminary studies prior to clinical trials. We present an in silico approach to the design of optimal pramlintide-to-insulin (P/I) ratios, using our computer simulator of the human metabolic system, with a population of virtual adult type 1 diabetes mellitus patients and with individual parameters modified to ac

Source: peer_reviewed_research
DOI: 10.1089/dia.2013.0054
PubMed: 23865841

Open original source

2013Insufficient evidence

Novel therapies for the management of type 2 diabetes mellitus: part 1. pramlintide and bromocriptine-QR.

Content-verified record concerning Pramlintide: "Novel therapies for the management of type 2 diabetes mellitus: part 1. pramlintide and bromocriptine-QR." Abstract excerpt: Several classes of antidiabetic agents have been introduced into the market place over the past dozen years. As our understanding of the underlying pathophysiology of type 2 diabetes has advanced, attempts have been made to address these defects specifically. This brief review focuses on our experience with two such pharmacological approaches: (i) a synthetic amylin analog addressing amylin defici

Source: systematic_review_or_meta_analysis
DOI: 10.1111/1753-0407.12034
PubMed: 23452312

Open original source

2020Insufficient evidence

Rediscovery of the Second β-Cell Hormone: Co-replacement With Pramlintide and Insulin in Type 1 Diabetes.

Content-verified record concerning Pramlintide: "Rediscovery of the Second β-Cell Hormone: Co-replacement With Pramlintide and Insulin in Type 1 Diabetes." (identity confirmed; no abstract text available to excerpt.)

Source: peer_reviewed_research
DOI: 10.2337/dci19-0077
PubMed: 32079687

Open original source

2006Insufficient evidence

Update in the pharmacologic treatment of diabetes mellitus: focus on pramlintide and exenatide.

Content-verified record concerning Pramlintide: "Update in the pharmacologic treatment of diabetes mellitus: focus on pramlintide and exenatide." Abstract excerpt: There are now more than 20 million people in America with diabetes mellitus (DM), and the prevalence of this illness continues to increase especially in those with type 2 DM. Over the past decade, research in the area of DM treatment has focused on pharmacologic approaches to modifying glucose metabolism as well as on lifestyle interventions to prevent and manage DM. Pharmacologic research has bee

Source: systematic_review_or_meta_analysis
DOI: 10.1177/0145721706294003
PubMed: 16971704

Open original source

1996Insufficient evidence

Effect of 14 days' subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM.

Content-verified record concerning Pramlintide: "Effect of 14 days' subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM." Abstract excerpt: Individuals with insulin-dependent diabetes mellitus (IDDM or type 1 diabetes) are deficient in both insulin and amylin, peptides secreted by the beta cell. We have investigated the effects of amylin replacement therapy employing the human amylin analogue, pramlintide (25, 28, 29-pro-human amylin, previously referred to as AC137), upon the responses to a standardized insulin infusion (40 mU. kg-1.

Source: peer_reviewed_research
DOI: 10.1007/bf00400683
PubMed: 8778001

Open original source

2014Insufficient evidence

Convergent chemoenzymatic synthesis of a library of glycosylated analogues of pramlintide: structure-activity relationships for amylin receptor agonism.

Content-verified record concerning Pramlintide: "Convergent chemoenzymatic synthesis of a library of glycosylated analogues of pramlintide: structure-activity relationships for amylin receptor agonism." Abstract excerpt: Pramlintide (Symlin®), a synthetic analogue of the naturally occurring pancreatic hormone amylin, is currently used with insulin in adjunctive therapy for type 1 and type 2 diabetes mellitus. Herein we report a systematic study into the effect that N-glycosylation of pramlintide has on activation of amylin receptors. A highly efficient convergent synthetic route, involving a combination of so

Source: peer_reviewed_research
DOI: 10.1039/c4ob01208a
PubMed: 25030939

Open original source

2013Insufficient evidence

Study reanalysis using a mechanism-based pharmacokinetic/pharmacodynamic model of pramlintide in subjects with type 1 diabetes.

Content-verified record concerning Pramlintide: "Study reanalysis using a mechanism-based pharmacokinetic/pharmacodynamic model of pramlintide in subjects with type 1 diabetes." Abstract excerpt: This report describes a pharmacokinetic/pharmacodynamic model for pramlintide, an amylinomimetic, in type 1 diabetes mellitus (T1DM). Plasma glucose and drug concentrations were obtained following bolus and 2-h intravenous infusions of pramlintide at three dose levels or placebo in 25 T1DM subjects during the postprandial period in a crossover study. The original clinical data were reanalyzed by m

Source: peer_reviewed_research
DOI: 10.1208/s12248-012-9409-7
PubMed: 23054970

Open original source

2013Insufficient evidence

Recent and emerging therapeutic medications in type 2 diabetes mellitus: incretin-based, Pramlintide, Colesevelam, SGLT2 Inhibitors, Tagatose, Succinobucol.

Content-verified record concerning Pramlintide: "Recent and emerging therapeutic medications in type 2 diabetes mellitus: incretin-based, Pramlintide, Colesevelam, SGLT2 Inhibitors, Tagatose, Succinobucol." Abstract excerpt: Nearly 285 million people worldwide, with 10% being Americans, suffer from diabetes mellitus and its associated comorbidities. This is projected to increase by 6.5% per year, with 439 million inflicted by year 2030. Both morbidity and mortality from diabetes stem from the consequences of microvascular and macrovascular complications. Of the 285 million with diabetes, over a quarter of a million di

Source: peer_reviewed_research
DOI: 10.1097/mjt.0b013e3181ec9eb2
PubMed: 20838206

Open original source

2009Insufficient evidence

Psychometric properties of an instrument for assessing treatment satisfaction associated with pramlintide use.

Content-verified record concerning Pramlintide: "Psychometric properties of an instrument for assessing treatment satisfaction associated with pramlintide use." Abstract excerpt: The clinical benefits of any new treatment depend substantially on patient acceptance and treatment satisfaction, because only well-accepted treatments will be widely used. Thus, it is important to understand how patients experience a new treatment. This study assessed the psychometric properties of a questionnaire (PRAM-TSQ) designed to measure treatment satisfaction in patients using pramlintide

Source: peer_reviewed_research
DOI: 10.1177/0145721708326989
PubMed: 19244569

Open original source

2008Insufficient evidence

Diabetes distress and its association with clinical outcomes in patients with type 2 diabetes treated with pramlintide as an adjunct to insulin therapy.

Content-verified record concerning Pramlintide: "Diabetes distress and its association with clinical outcomes in patients with type 2 diabetes treated with pramlintide as an adjunct to insulin therapy." Abstract excerpt: This study was designed to assess diabetes-related distress and its association with clinical outcomes in patients with type 2 diabetes using basal insulin who were treated with pramlintide. In a 16-week, double-blind, placebo-controlled study 211 patients using insulin glargine with or without oral antidiabetes agents were randomized to addition of pramlintide or placebo. Clinical outcomes (chang

Source: peer_reviewed_research
DOI: 10.1089/dia.2008.0031
PubMed: 19049375

Open original source

2010Insufficient evidence

Comparison of the post-meal glucose response to different insulin bolus waveforms in insulin pump- and pre-meal pramlintide-treated type 1 diabetes patients.

Content-verified record concerning Pramlintide: "Comparison of the post-meal glucose response to different insulin bolus waveforms in insulin pump- and pre-meal pramlintide-treated type 1 diabetes patients." Abstract excerpt: Both pramlintide and insulin pump waveforms separately provide improved post-meal glucose control. However, when used together there may be a mismatch in actions leading to hypoglycemia. We studied the three currently available waveforms and a "modified combination wave" (MC) in pramlintide-treated patients. The MC was a "square" (SQ) wave combined with a "standard" (ST) bolus that was delayed 1 h

Source: peer_reviewed_research
DOI: 10.1089/dia.2009.0096
PubMed: 20105039

Open original source

2007Insufficient evidence

Pharmacokinetics of an oral drug (acetaminophen) administered at various times relative to subcutaneous injection of pramlintide in subjects with type 2 diabetes.

Content-verified record concerning Pramlintide: "Pharmacokinetics of an oral drug (acetaminophen) administered at various times relative to subcutaneous injection of pramlintide in subjects with type 2 diabetes." Abstract excerpt: Pramlintide, an adjunct treatment to mealtime insulin for patients with type 2 and type 1 diabetes, aids glycemic control by suppressing postprandial glucagon secretion, slowing gastric emptying, and enhancing satiety. Because gastric emptying affects oral medication absorption, this placebo-controlled, single-blind, crossover study examined the absorption of 1000 mg of acetaminophen elixir admini

Source: peer_reviewed_research
DOI: 10.1177/0091270007300949
PubMed: 17463219

Open original source

2025Insufficient evidence

A Pilot Outpatient Assessment of a Fully Closed-Loop Insulin and Pramlintide System.

Pilot evaluation of a combined insulin-pramlintide system; no claim about pramlintide alone.

Source: peer_reviewed_research
DOI: 10.1177/19322968251371046
PubMed: 41174925

Open original source

2016Insufficient evidence

Mitigating Meal-Related Glycemic Excursions in an Insulin-Sparing Manner During Closed-Loop Insulin Delivery: The Beneficial Effects of Adjunctive Pramlintide and Liraglutide.

Content-verified record concerning Pramlintide: "Mitigating Meal-Related Glycemic Excursions in an Insulin-Sparing Manner During Closed-Loop Insulin Delivery: The Beneficial Effects of Adjunctive Pramlintide and Liraglutide." Abstract excerpt: Closed-loop (CL) insulin delivery effectively maintains glucose overnight but struggles when challenged with meals. Use of single-day, 30-μg/meal pramlintide lowers meal excursions during CL. We sought to further elucidate the potential benefits of adjunctive agents after 3-4 weeks of outpatient dose titration. Two CL studies were conducted: one evaluating adjunctive pramlintide and the othe

Source: peer_reviewed_research
DOI: 10.2337/dc16-0089
PubMed: 27208332

Open original source

2007Insufficient evidence

Therapies for diabetes: pramlintide and exenatide.

Content-verified record concerning Pramlintide: "Therapies for diabetes: pramlintide and exenatide." Abstract excerpt: The American Diabetes Association currently recommends an A1C goal of less than 7 percent. However, many patients are unable to achieve this goal by using oral drug combinations or diet and exercise, leaving insulin as the only treatment option. In most cases, insulin is initiated later in therapy because of its inconvenience and adverse effects (e.g., weight gain, hypoglycemia, possible role in a

Source: peer_reviewed_research
PubMed: 17619527

Open original source

2022Insufficient evidence

Pramlintide: A Novel Therapeutic Approach for Osteosarcoma through Metabolic Reprogramming.

Content-verified record concerning Pramlintide: "Pramlintide: A Novel Therapeutic Approach for Osteosarcoma through Metabolic Reprogramming." Abstract excerpt: Despite aggressive combination chemotherapy and surgery, outcomes for patients with osteosarcoma have remained stagnant for more than 25 years, and numerous clinical trials have identified no new therapies. p53 deletion or mutation is found in more than 80% of osteosarcoma tumors. In p53-deficient cancers with structurally altered p63 and p73, interfering with tumor cell metabolism using Pramlinti

Source: peer_reviewed_research
DOI: 10.3390/cancers14174310
PubMed: 36077845

Open original source

2018Insufficient evidence

Pramlintide but Not Liraglutide Suppresses Meal-Stimulated Glucagon Responses in Type 1 Diabetes.

Content-verified record concerning Pramlintide: "Pramlintide but Not Liraglutide Suppresses Meal-Stimulated Glucagon Responses in Type 1 Diabetes." Abstract excerpt: Postprandial hyperglycemia remains a challenge in type 1 diabetes (T1D) due, in part, to dysregulated increases in plasma glucagon levels after meals. This study was undertaken to examine whether 3 to 4 weeks of therapy with pramlintide or liraglutide might help to blunt postprandial hyperglycemia in T1D by suppressing plasma glucagon responses to mixed-meal feedings. Two parallel studies were con

Source: peer_reviewed_research
DOI: 10.1210/jc.2017-02265
PubMed: 29211871

Open original source

2017Insufficient evidence

Efficacy and safety of pramlintide injection adjunct to insulin therapy in patients with type 1 diabetes mellitus: a systematic review and meta-analysis.

Content-verified record concerning Pramlintide: "Efficacy and safety of pramlintide injection adjunct to insulin therapy in patients with type 1 diabetes mellitus: a systematic review and meta-analysis." Abstract excerpt: We aim to assess the efficacy and safety of pramlintide plus insulin therapy in patients with type 1 diabetes. We included clinical studies comparing pramlintide plus insulin to placebo plus insulin. Efficacy was reflected by glycemic control and reduction in body weight and insulin use. Safety concerns were hypoglycemia and other adverse events. Subgroup analysis was performed for different doses

Source: systematic_review_or_meta_analysis
DOI: 10.18632/oncotarget.16008
PubMed: 29029531

Open original source

2006Insufficient evidence

Pramlintide in the treatment of diabetes.

Content-verified record concerning Pramlintide: "Pramlintide in the treatment of diabetes." Abstract excerpt: Diabetes treatment has traditionally focused on correcting insulin deficiency with exogenous insulin and oral agents designed to enhance insulin secretion or insulin sensitivity in peripheral tissues. The more recent view of diabetes as a disease that affects multiple hormones in addition to insulin has led to the development of new therapies more broadly aimed at restoring glucose homeostasis by

Source: peer_reviewed_research
DOI: 10.1111/j.1742-1241.2006.01187.x
PubMed: 17109671

Open original source

1999Insufficient evidence

USAN Council. List No. 419. New names. Pramlintide acetate.

Content-verified record concerning Pramlintide: "USAN Council. List No. 419. New names. Pramlintide acetate." (identity confirmed; no abstract text available to excerpt.)

Source: peer_reviewed_research
PubMed: 10576958

Open original source

2006Insufficient evidence

Pramlintide in the management of insulin-using patients with type 2 and type 1 diabetes.

Content-verified record concerning Pramlintide: "Pramlintide in the management of insulin-using patients with type 2 and type 1 diabetes." Abstract excerpt: In patients with diabetes, dysregulation of multiple glucoregulatory hormones results in chronic hyperglycemia and an array of associated microvascular and macrovascular complications. Optimization of glycemic control, both overall (glycosylated hemoglobin [A1C]) and in the postprandial period, may reduce the risk of long-term vascular complications. However, despite significant recent therapeutic

Source: peer_reviewed_research
DOI: 10.2147/vhrm.2006.2.3.203
PubMed: 17326327

Open original source

2009Insufficient evidence

Pramlintide in pediatric type 1 diabetes.

Content-verified record concerning Pramlintide: "Pramlintide in pediatric type 1 diabetes." (identity confirmed; no abstract text available to excerpt.)

Source: peer_reviewed_research
DOI: 10.1016/j.jpeds.2009.04.065
PubMed: 19732574

Open original source

2005Insufficient evidence

Pramlintide (symlin) for diabetes.

Content-verified record concerning Pramlintide: "Pramlintide (symlin) for diabetes." Abstract excerpt: An injected analog of human amylin used as an adjunct to insulin.

Source: peer_reviewed_research
PubMed: 15912124

Open original source

2007Insufficient evidence

Pramlintide treatment reduces 24-h caloric intake and meal sizes and improves control of eating in obese subjects: a 6-wk translational research study.

Content-verified record concerning Pramlintide: "Pramlintide treatment reduces 24-h caloric intake and meal sizes and improves control of eating in obese subjects: a 6-wk translational research study." Abstract excerpt: Evidence from rodent studies indicates that the beta-cell-derived neurohormone amylin exerts multiple effects on eating behavior, including reductions in meal size, intake of highly palatable foods, and stress-induced sucrose consumption. To assess the effect of amylin agonism on human eating behavior we conducted a randomized, blinded, placebo-controlled, multicenter study investigating the effec

Source: peer_reviewed_research
DOI: 10.1152/ajpendo.00217.2007
PubMed: 17505051

Open original source

2002Insufficient evidence

Pramlintide: an agent for glycemic control plus weight control?

Content-verified record concerning Pramlintide: "Pramlintide: an agent for glycemic control plus weight control?" (identity confirmed; no abstract text available to excerpt.)

Source: peer_reviewed_research
DOI: 10.1089/15209150252924102
PubMed: 12017422

Open original source

Insufficient evidence